ES2971286T3 - Aplicación de interacciones cromosómicas epigenéticas en diagnóstico de cáncer - Google Patents
Aplicación de interacciones cromosómicas epigenéticas en diagnóstico de cáncer Download PDFInfo
- Publication number
- ES2971286T3 ES2971286T3 ES17817030T ES17817030T ES2971286T3 ES 2971286 T3 ES2971286 T3 ES 2971286T3 ES 17817030 T ES17817030 T ES 17817030T ES 17817030 T ES17817030 T ES 17817030T ES 2971286 T3 ES2971286 T3 ES 2971286T3
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- chromosomal
- cancer
- probe
- interaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003993 interaction Effects 0.000 title claims abstract description 215
- 230000002759 chromosomal effect Effects 0.000 title claims abstract description 130
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 65
- 201000011510 cancer Diseases 0.000 title claims abstract description 57
- 230000001973 epigenetic effect Effects 0.000 title claims abstract description 40
- 238000003745 diagnosis Methods 0.000 title claims description 4
- 238000000034 method Methods 0.000 claims abstract description 98
- 230000000295 complement effect Effects 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 140
- 239000000523 sample Substances 0.000 claims description 136
- 102000039446 nucleic acids Human genes 0.000 claims description 120
- 108020004707 nucleic acids Proteins 0.000 claims description 120
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 238000001514 detection method Methods 0.000 claims description 50
- 210000000349 chromosome Anatomy 0.000 claims description 49
- 238000003753 real-time PCR Methods 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 239000002773 nucleotide Substances 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 29
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 27
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 21
- 101000846284 Homo sapiens Pre-mRNA 3'-end-processing factor FIP1 Proteins 0.000 claims description 21
- 102100031755 Pre-mRNA 3'-end-processing factor FIP1 Human genes 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 20
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 19
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 19
- 238000004393 prognosis Methods 0.000 claims description 15
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 14
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 14
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 14
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 13
- 208000005017 glioblastoma Diseases 0.000 claims description 13
- 208000024364 idiopathic hypereosinophilic syndrome Diseases 0.000 claims description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 5
- 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000005304 joining Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011895 specific detection Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 9
- 238000013519 translation Methods 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 51
- 238000003752 polymerase chain reaction Methods 0.000 description 47
- 239000012634 fragment Substances 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 201000010099 disease Diseases 0.000 description 27
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 25
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 229960002411 imatinib Drugs 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 23
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 23
- 230000007062 hydrolysis Effects 0.000 description 22
- 238000006460 hydrolysis reaction Methods 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 18
- 230000003211 malignant effect Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 16
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 15
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 15
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 14
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000000306 recurrent effect Effects 0.000 description 14
- 206010018338 Glioma Diseases 0.000 description 13
- 230000003321 amplification Effects 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 13
- 208000024207 chronic leukemia Diseases 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 208000032612 Glial tumor Diseases 0.000 description 10
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 9
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 230000001394 metastastic effect Effects 0.000 description 9
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 7
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 7
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 7
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 7
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000003483 chromatin Anatomy 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000008995 epigenetic change Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229950008516 olaratumab Drugs 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 6
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 6
- 201000004085 CLL/SLL Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 6
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 6
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 208000023958 prostate neoplasm Diseases 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- DUCNNEYLFOQFSW-PMERELPUSA-N (7S)-1-[(4-fluorophenyl)methyl]-3-N-(4-methoxy-3,5-dimethylphenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,6-dihydropyrazolo[4,3-c]pyridine-3,7-dicarboxamide Chemical compound COc1c(C)cc(NC(=O)c2nn(Cc3ccc(F)cc3)c3c2CN(C[C@]3(C)C(N)=O)C(=O)c2ccc[nH]2)cc1C DUCNNEYLFOQFSW-PMERELPUSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 5
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 5
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 229960002448 dasatinib Drugs 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 5
- 229950010895 midostaurin Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 206010000830 Acute leukaemia Diseases 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 4
- 208000004860 Blast Crisis Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 101150000637 EOL1 gene Proteins 0.000 description 4
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 4
- -1 KIT Proteins 0.000 description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 4
- 229950009240 crenolanib Drugs 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007419 epigenetic assay Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 3
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 description 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 description 3
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 208000017760 chronic graft versus host disease Diseases 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 description 3
- 229950005778 dovitinib Drugs 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 208000029824 high grade glioma Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 208000000516 mast-cell leukemia Diseases 0.000 description 3
- 208000008585 mastocytosis Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 102200069690 rs121913500 Human genes 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical group COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 2
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 2
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 2
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 2
- 229960002412 cediranib Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 2
- 229960004655 masitinib Drugs 0.000 description 2
- 201000000638 mature B-cell neoplasm Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 208000010915 neoplasm of mature B-cells Diseases 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229950001626 quizartinib Drugs 0.000 description 2
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 102220211621 rs11554137 Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940068117 sprycel Drugs 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940069905 tasigna Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 229950000578 vatalanib Drugs 0.000 description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 2
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000035131 DNA demethylation Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 101710198293 Guanylyl cyclase C Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102100027673 NCK-interacting protein with SH3 domain Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- MHHMNDJIDRZZNT-UHFFFAOYSA-N atto 680 Chemical compound OC(=O)CCCN1C(C)(C)C=C(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 MHHMNDJIDRZZNT-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000016632 ovarian clear cell cancer Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2971286T3 true ES2971286T3 (es) | 2024-06-04 |
Family
ID=60702831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17817030T Active ES2971286T3 (es) | 2016-12-01 | 2017-11-30 | Aplicación de interacciones cromosómicas epigenéticas en diagnóstico de cáncer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (enExample) |
| EP (2) | EP4357463A3 (enExample) |
| JP (2) | JP2019535295A (enExample) |
| KR (1) | KR102481242B1 (enExample) |
| CN (1) | CN110234769B (enExample) |
| AU (1) | AU2017367245B2 (enExample) |
| CA (1) | CA3045070A1 (enExample) |
| ES (1) | ES2971286T3 (enExample) |
| MY (1) | MY190153A (enExample) |
| PL (1) | PL3548633T3 (enExample) |
| TW (1) | TWI865427B (enExample) |
| WO (1) | WO2018100381A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225551A1 (en) * | 2019-05-08 | 2020-11-12 | Oxford BioDynamics PLC | Chromosome conformation markers of prostate cancer and lymphoma |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564262A (en) * | 2005-07-04 | 2010-02-26 | Univ Erasmus Medical Ct | Chromosome conformation capture-on-chip (4C) assay |
| GB0603251D0 (en) * | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| AU2008204338B2 (en) * | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
| CA2609172A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Utah Research Foundation | Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| GB0810051D0 (en) * | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| WO2010036323A1 (en) | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
| EP2366162A1 (en) * | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
| CA2804450C (en) * | 2010-07-09 | 2022-10-11 | Max Jan van Min | 3-d genomic region of interest sequencing strategies |
| US20140056898A1 (en) * | 2011-02-24 | 2014-02-27 | Bo Zhang | Combination therapies comprising anti-erbb3 agents |
| EP2710146A2 (en) * | 2011-05-18 | 2014-03-26 | Life Technologies Corporation | Chromosome conformation analysis |
| AU2013280644B2 (en) * | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN102827935B (zh) * | 2012-08-29 | 2013-12-18 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| JP2018518203A (ja) | 2015-06-24 | 2018-07-12 | オックスフォード バイオダイナミックス リミテッド | エピジェネティックな染色体相互作用 |
| EP3390656B1 (en) * | 2015-12-14 | 2020-04-08 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018100381A1 (en) | 2018-06-07 |
| CA3045070A1 (en) | 2018-06-07 |
| TW201842190A (zh) | 2018-12-01 |
| TWI865427B (zh) | 2024-12-11 |
| NZ753716A (en) | 2024-05-31 |
| MY190153A (en) | 2022-03-31 |
| KR20190086569A (ko) | 2019-07-22 |
| CN110234769B (zh) | 2024-06-07 |
| US11560597B2 (en) | 2023-01-24 |
| KR102481242B1 (ko) | 2022-12-23 |
| AU2017367245B2 (en) | 2020-09-24 |
| EP3548633B1 (en) | 2024-01-24 |
| PL3548633T3 (pl) | 2024-04-02 |
| JP2023027076A (ja) | 2023-03-01 |
| US20230082230A1 (en) | 2023-03-16 |
| EP4357463A3 (en) | 2024-07-17 |
| EP3548633A1 (en) | 2019-10-09 |
| EP3548633C0 (en) | 2024-01-24 |
| JP7579003B2 (ja) | 2024-11-07 |
| AU2017367245A1 (en) | 2019-06-06 |
| CN110234769A (zh) | 2019-09-13 |
| EP4357463A2 (en) | 2024-04-24 |
| US20190338367A1 (en) | 2019-11-07 |
| JP2019535295A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105102635B (zh) | 肺癌的分类和可行性指数 | |
| KR102622307B1 (ko) | 후성유전적 염색체 상호작용 | |
| US8637245B2 (en) | Method for the detection of EGFR mutations in blood samples | |
| EP3464593B1 (en) | Molecular tagging methods and sequencing libraries | |
| CN109661477B (zh) | 与乳腺癌相关的染色体相互作用的检测 | |
| JP2010535473A5 (enExample) | ||
| ES2987603T3 (es) | Regulación genética de la respuesta inmunitaria por interacciones cromosómicas | |
| EP3507384B1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| Tian et al. | Single locked nucleic acid-enhanced nanopore genetic discrimination of pathogenic serotypes and cancer driver mutations | |
| US20180155795A1 (en) | Classification and actionability indices for cancer | |
| JP7579003B2 (ja) | がんの診断における後成的染色体相互作用の応用 | |
| JP6453781B2 (ja) | ヒトｐｉ３ｋｃａ（ｐｉｋ３ｃａ）遺伝子変異検出のための方法及び組成物 | |
| WO2015149720A1 (en) | Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer | |
| Roohi et al. | A de novo apparently balanced translocation [46, XY, t (2; 9)(p13; p24)] interrupting RAB11FIP5 identifies a potential candidate gene for autism spectrum disorder | |
| KR20220007132A (ko) | 전립선암 및 림프종의 염색체 형태 마커 | |
| CN110358835A (zh) | 生物标志物在胃癌检测、诊断中的应用 | |
| CN111349691A (zh) | Egfr基因缺失突变检测用组合物、试剂盒及检测方法 | |
| HK40111334A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| HK40013967B (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| HK40013967A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| Gallegos-Ruiz | Therapeutic targets and biomarkers in lung cancer | |
| Chorostowska-Wynimko et al. | Genetic biomarkers in lung cancer therapy-an update |